NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

Engitix Ltd (“Engitix”), a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a $25 million Series A ...

The University Hospital Zurich (USZ) is one of Europe’s leading academic medical centers, offering cutting-edge clinical care and internationally recognized diagnostic expertise. The Department of ...

Waqf, an Islamic endowment that involves the permanent transfer of wealth for a charitable purpose, is a common form of good deed recommended in Islamic teachings (Sunnah practice). A joint report by ...

“We are very pleased with the Phase 1 results for AGMB-447 announced today. The data point to a generally favorable safety, tolerability and PK profile of AGMB-447 and show proof-of-mechanism of ...

“We are delighted to welcome Larry to the board of Onco3R as Chairman” said Pierre Raboisson, PhD, CEO and Founder of Onco3R Therapeutics. “He brings a perfect mixture of strategic acumen, deep ...

Telix will host a presentation on Monday, 12 January at 9:00 am PST (12:00 pm EST / 4:00 am AEDT, 13 January), providing an overview of the Company’s pipeline assets alongside its commercial portfolio ...

Preliminary shotgun metagenomic sequencing demonstrated that EBX-102-02 induced a broad and sustained shift in the gut microbiome towards the composition of the administered product. These changes ...

Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M ...

During 2025, Aclarion continued to build on its mission to transform the diagnosis of chronic low back pain achieving 69% year-over-year scan volume growth. Nociscan scan volumes increased +114% ...

Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, ...